We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
In the latest close session, Gilead Sciences (GILD - Free Report) was down 1.87% at $144.74. The stock's change was less than the S&P 500's daily gain of 0.73%. Elsewhere, the Dow saw an upswing of 0.49%, while the tech-heavy Nasdaq appreciated by 1.19%.
Coming into today, shares of the HIV and hepatitis C drugmaker had lost 2.46% in the past month. In that same time, the Medical sector lost 3.74%, while the S&P 500 gained 0.55%.
Analysts and investors alike will be keeping a close eye on the performance of Gilead Sciences in its upcoming earnings disclosure. On that day, Gilead Sciences is projected to report earnings of $2.15 per share, which would represent a year-over-year decline of 12.96%. Alongside, our most recent consensus estimate is anticipating revenue of $7.79 billion, indicating a 0.3% upward movement from the same quarter last year.
GILD's full-year Zacks Consensus Estimates are calling for earnings of -$0.48 per share and revenue of $30.74 billion. These results would represent year-over-year changes of -105.89% and +4.4%, respectively.
Investors should also take note of any recent adjustments to analyst estimates for Gilead Sciences. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been a 0.19% rise in the Zacks Consensus EPS estimate. Gilead Sciences is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 181, which puts it in the bottom 27% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
In the latest close session, Gilead Sciences (GILD - Free Report) was down 1.87% at $144.74. The stock's change was less than the S&P 500's daily gain of 0.73%. Elsewhere, the Dow saw an upswing of 0.49%, while the tech-heavy Nasdaq appreciated by 1.19%.
Coming into today, shares of the HIV and hepatitis C drugmaker had lost 2.46% in the past month. In that same time, the Medical sector lost 3.74%, while the S&P 500 gained 0.55%.
Analysts and investors alike will be keeping a close eye on the performance of Gilead Sciences in its upcoming earnings disclosure. On that day, Gilead Sciences is projected to report earnings of $2.15 per share, which would represent a year-over-year decline of 12.96%. Alongside, our most recent consensus estimate is anticipating revenue of $7.79 billion, indicating a 0.3% upward movement from the same quarter last year.
GILD's full-year Zacks Consensus Estimates are calling for earnings of -$0.48 per share and revenue of $30.74 billion. These results would represent year-over-year changes of -105.89% and +4.4%, respectively.
Investors should also take note of any recent adjustments to analyst estimates for Gilead Sciences. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been a 0.19% rise in the Zacks Consensus EPS estimate. Gilead Sciences is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 181, which puts it in the bottom 27% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.